Buscar en
Inmunología
Toda la web
Inicio Inmunología Surfing the waves of the tide model of T cell co-stimulation
Información de la revista
Vol. 31. Núm. 1.
Páginas 31-33 (Enero - Marzo 2012)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
4014
Vol. 31. Núm. 1.
Páginas 31-33 (Enero - Marzo 2012)
Panorama
DOI: 10.1016/j.inmuno.2011.09.001
Acceso a texto completo
Surfing the waves of the tide model of T cell co-stimulation
Surfeando las olas del modelo en marea de co-estimulación de células T
Visitas
...
Elena Marín-Díez, Iván Martínez-Forero, Ignacio Melero, Asís Palazón??
Autor para correspondencia
fpalazon@alumni.unav.es

Corresponding author.
Centro de Investigación Médica Aplicada (CIMA), Facultad de Medicina y Clínica Universitaria, Universidad de Navarra, Pamplona, Spain
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (2)
Texto completo
Control of the immune responses by co-stimulation and co-inhibition

As a theoretical model it is postulated that T cells require two signals for appropriate activation.1 Signal 1 is started after T cell receptor binding to a MHC–peptide complex on the surface of an antigen presenting cell. Signal 2 is delivered by co-stimulatory molecules including CD28 that binds to CD80 and CD86.2 Negative regulators modulate the grade of T cell activation and protect the organism of deleterious effects mediated by uncontrolled T cell activation.3 CTLA-4 is one of these co-inhibitory molecules expressed on activated T cells.4,5 It recognises CD80 and CD86 with an affinity 200 times higher than CD28.6 Therapeutic strategies directed to promote or interfere with CTLA-4 function are now in clinical use for autoimmunity (i.e. Abatacept)7 and cancer (Ipilimumab).8

As new cell surface signaling molecules and interactions are being discovered, the two-signal model becomes insufficient to explain the resulting immune response. Co-stimulatory or co-inhibitory molecules belong to structurally different families of receptors including the tumor necrosis factor (TNF) receptor superfamily, immunoglobulin family or to the B7 family. Interestingly, interactions between members of different families are also possible.9 The different distribution of surface proteins between different immune populations as well as the influence of particular microenvironments provides outstanding diversity to the regulation of immunity.10 Signals from many receptors determine the intensity and the type of ensuing immune response. Integration of multiple elements determine the level of the tide (Fig. 1).

Fig. 1.

Co-stimulatory and co-inhibitory interactions between members between the Ig superfamily.

(0,13MB).
The receptor array

The historical approach to identify new co-stimulatory and co-inhibitory molecules started in the 60s with the usage of monoclonal antibodies used as a bait. Then in the 90s bioinformatic studies allowed identification of new surface receptors based on sequence similarity. In the 2000s the main strategy to identify new interactions between surface cosignaling molecules has been systemic monitoring of molecular events: expression cloning, immunoprecipitation and subsequent high efficiency molecular structure identification.

In a seminal paper, Chen et al. describe a new technology dubbed “receptor array” that allows a high throughoutput detection of binding partners.11 The assay starts with the cloning of more than 2500 full-length human transmembrane protein genes to be tested individually. It consists of simultaneous transfections of 293T cells on multi-well plates. Each well contains the transfectants for a single surface molecule. The screening is performed with the protein of interest tagged with a fused peptide (FLAG or HA). After incubation with a fluorescent-labeled secondary antibody against the tag, an automatized detection system screens the wells in which the plate-coating cell layer displays fluorescence. The system excludes the background signal coming from solubilized secondary antibody that has not encountered the tagged protein bound to the putative receptor expressed by the 293T transfected cells.

Identification of CD28 and CTLA-4 as new receptors for B7H2 (ICOS-L)

Identification of CD28 and CTLA-4 as new receptors for B7H2 (ICOS-L) B7H2, also known as ICOS ligand, binds inducible-co-stimulator (ICOS) on activated T cells.12 Using the receptor array described before, Chen et al. were able to identify a new interactions between B7H2–CD28 and B7H2–CTLA-4. Regarding the affinity hierarchy between B7H2 and their cognate ligands, ICOS has the highest followed by CTLA-4 and CD28.

Binding of B7H2 to CD28 increases T cell proliferation and IFN-γ production on T cells. Although the interaction between B7H2 and CTLA-4 has been described, the functional consequences on T cells have not been fully explored yet due to the difficulty of isolating the effect on CTLA-4 on in vitro assays.

Targeting PD-1–PD-L1 interactions as a therapeutic approach to treat cancer

Monoclonal antibodies (mAbs) provide a valuable pharmacological tool to overactivate co-stimulatory signals and inactivate co-inhibitory functions of surface receptors on T cells in the context of cancer therapeutics.13 One of the promising emerging targets in cancer immunotherapy is the pair formed by PD-L1 and PD-1.14

PD-1 is a co-inhibitory receptor that shows homology with CD28 and whose expression is induced after activation on CD4+ and CD8+ T cells as well as on other immune cells. Its cognate ligands are the members of the B7 family PDL1 (B7H1) and B7-DC (PD-L2) and other yet unreported unknown protein. PD-1 triggering on the T cell leads to a non pro-apoptotic inhibition of T cell proliferation. Because of these modulator effects it is known as an immune checkpoint along with CTLA-4.

PD-L1 was discovered on the APC15 and binds PD-1, CD80 (B7-1) and other yet unreported unknown protein. Its expression can be induced in almost all nucleated cell types by the action of IFN-γ,16 TLR agonists17 and loss of PTEN/activation of PI3K.18 The PD-L1 expression has been also described on tumor cells, correlating with a poor prognosis of the disease. Interestingly, IFN-γ induces PD-L1 expression in vitro on both murine and human tumor cell lines that do not express the protein constitutively. The hypothetic implications of this induction in vivo are shown (Fig. 2).

Fig. 2.

IFN-γ production by activated T cells in the tumor microenvironment elicits the expression of B7H1 (PD-L1) in tumor cells that in turn repress cytotoxic T-cell functions via PD-1.

(0,16MB).

Human anti-PD1 mAb (MDX1101) are already in early clinical trials for cancer. Preliminary data on overall response upon multiple doses of this agent indicates 30% in metastatic melanoma. The agents seem to be clinically active also on colorectal cancer, lung cancer and renal cell carcinoma.

Acknowledgements

We are grateful for support from MEC (SAF2005-03131 and SAF2008-03294), Departamento de Educación del Gobierno de Navarra, Departamento de Salud del Gobierno de Navarra (Beca Ortiz de Landázuri), Redes temáticas de investigación cooperativa RETIC (RD06/0020/0065), Fondo de investigación sanitaria (PI060932), European commission VII famework program (ENCITE), Fundacion Mutua Madrileña, and “UTE for project FIMA”. A.-P. receives an isciii predoctoral fellowship.

References
[1]
K.J. Lafferty, A.J. Cunningham.
A new analysis of allogeneic interactions.
Aust J Exp Biol Med Sci, 53 (1975), pp. 27-42
[2]
D.J. Lenschow, T.L. Walunas, J.A. Bluestone.
CD28/B7 system of T cell costimulation.
Annu Rev Immunol, 14 (1996), pp. 233-258
[3]
C.E. Rudd, H. Schneider.
Unifying concepts in CD28, ICOS and CTLA4 coreceptor signalling.
Nat Rev Immunol, 3 (2003), pp. 544-556
[4]
S. Chikuma, J.A. Bluestone.
CTLA-4 and tolerance: the biochemical point of view.
Immunol Res, 28 (2003), pp. 241-253
[5]
M.F. Krummel, J.P. Allison.
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
J Exp Med, 182 (1995), pp. 459-465
[6]
A.H. Sharpe.
Mechanisms of costimulation.
[7]
M.L. Alegre, F. Fallarino.
Mechanisms of CTLA-4-Ig in tolerance induction.
Curr Pharm Des, 12 (2006), pp. 149-160
[8]
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
[9]
L.C. Gonzalez, K.M. Loyet, J. Calemine-Fenaux, J. Calemine-Fenaux, V. Chauhan, B. Wranik, et al.
A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
Proc Natl Acad Sci USA, 102 (2005), pp. 1116-1121
[10]
Zhu Y, Yao S, Chen L. Cell surface signaling molecules in the control of immune responses: a tide model. Immunity. 2011;34:466–78.
[11]
Yao S, Zhu Y, Zhu G, Augustine M, Zheng L, Goode DJ, et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity. 2011;34:729–40.
[12]
A. Hutloff, A.M. Dittrich, K.C. Beier, B. Eljaschewitsch, R. Kraft, I. Anagnostopoulos, et al.
ICOS is an inducible T-cell costimulator structurally and functionally related to CD28.
Nature, 397 (1999), pp. 263-266
[13]
I. Melero, S. Hervas-Stubbs, M. Glennie, D.M. Pardoll, L. Chen.
Immunostimulatory monoclonal antibodies for cancer therapy.
Nat Rev Cancer, 7 (2007), pp. 95-106
[14]
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2011;28:3167–75.
[15]
G.J. Freeman, A.J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, et al.
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
J Exp Med, 192 (2000), pp. 1027-1034
[16]
F. Hirano, K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, et al.
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
Cancer Res, 65 (2005), pp. 1089-1096
[17]
V. Pulko, X. Liu, C.J. Krco, K.J. Harris, X. Frigola, E.D. Kwon, et al.
TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination.
J Immunol, 183 (2009), pp. 3634-3641
[18]
Y.E. Latchman, S.C. Liang, Y. Wu, T. Chernova, R.A. Sobel, M. Klemm, et al.
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
Proc Natl Acad Sci USA, 101 (2004), pp. 10691-10696

A summary of the closing lecture at the XXXVI SEI congress (University of Navarra) presented by Prof. Lieping Chen (Yale University).

Copyright © 2011. Sociedad Española de Inmunología
Opciones de artículo
Herramientas